CONTOVIR: a new adjuvant therapy in recurrent respiratory papillomatosis
Phase 3
- Conditions
- Recurrent respiratory papillomatosis.Benign neoplasm of middle ear and respiratory system (adenomatose polyps)
- Registration Number
- IRCT2013101214986N1
- Lead Sponsor
- Ear, nose, throat, head and neck department and research center of Iran University of Medical Scienc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
1- all patients with Recurrent Respiratory Papillomatosis diagnosed by 2 ENT specialist.
Exclusion Criteria
1- No other severe respiratory disease (TB, ...).
2- No other severe inflammatory disease (RA, SLE, ...).
3- No history of surgery during the treatment time of treatment and one year before the study.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of RRP recurrence. Timepoint: Surgeries during one year after adjuvant therapy. Method of measurement: Calender.
- Secondary Outcome Measures
Name Time Method Disease severity. Timepoint: Clinical (voice and auscultation) Anatomical (number and type of polyps). Method of measurement: staging system described by Derkay et al (Derkay, D.A.L.a.C.S., Epidemiology of recurrent respiratory papillomatosis. APMIS, 2010. 118: p. 450-454.).